GlassScriptPhysician profile
Jeffrey R Brown
NPI 1942403399
$3,558.74
in general payments reported to CMS, 2019-2025
33 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $333 · 2021: $199 · 2022: $434 · 2023: $589 · 2024: $600 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.21 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $444.08 | 2019-2025 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $420.04 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.32 | 2019-2025 | Jardiance, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $364.08 | 2019-2025 | |
| Novo Nordisk INC | $302.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $218.74 | 2019-2025 | |
| Lilly USA, LLC | $158.69 | 2022-2025 | Mounjaro, Trulicity |
| Medtronic Vascular, INC. | $135.80 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $129.47 | 2025 | Uptravi, Opsumit |
| W. L. Gore & Associates, INC. | $121.72 | 2022-2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| E.R. Squibb & Sons, L.L.C. | $110.03 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $95.82 | 2021-2025 | Cardiomems, Mitraclip |
| Boston Scientific Corporation | $85.92 | 2021-2025 | Watchman Access System, Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $71.87 | 2019 | |
| Scpharmaceuticals INC. | $63.37 | 2025 |
Show all 33 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.